Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects

Trial Profile

Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary) ; Methotrexate
  • Indications Pelvic inflammatory disorders; Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 10 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 05 Jul 2018 Planned End Date changed from 15 Jun 2018 to 10 Jul 2018.
    • 08 Jun 2018 Planned End Date changed from 10 May 2018 to 15 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top